Media coverage about Cerus Corporation (NASDAQ:CERS) has been trending somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerus Corporation earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.0653315421025 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern’s rankings:

CERS has been the subject of a number of recent analyst reports. Cowen and Company set a $6.00 target price on Cerus Corporation and gave the stock a “buy” rating in a research report on Thursday, October 5th. Zacks Investment Research raised Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Monday. BidaskClub cut Cerus Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. Finally, ValuEngine cut Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Cerus Corporation currently has an average rating of “Hold” and an average target price of $7.00.

Cerus Corporation (NASDAQ:CERS) traded down 1.32% during midday trading on Wednesday, hitting $3.00. The stock had a trading volume of 641,162 shares. The firm has a 50-day moving average price of $2.75 and a 200-day moving average price of $2.84. Cerus Corporation has a 1-year low of $1.93 and a 1-year high of $5.91. The firm’s market capitalization is $327.41 million.

Cerus Corporation (NASDAQ:CERS) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). Cerus Corporation had a negative return on equity of 120.31% and a negative net margin of 164.39%. The company had revenue of $9.53 million during the quarter, compared to the consensus estimate of $9.14 million. During the same period in the previous year, the company posted ($0.18) EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, equities research analysts anticipate that Cerus Corporation will post ($0.64) earnings per share for the current year.

In other Cerus Corporation news, insider Laurence M. Corash bought 92,796 shares of Cerus Corporation stock in a transaction dated Friday, August 11th. The stock was bought at an average cost of $2.45 per share, for a total transaction of $227,350.20. Following the purchase, the insider now owns 1,375,711 shares of the company’s stock, valued at approximately $3,370,491.95. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.40% of the company’s stock.

WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Cerus Corporation (CERS) Share Price” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cerus-corporation-cers-share-price/1639668.html.

About Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus Corporation (NASDAQ:CERS)

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.